AGC Biologics adds 2,000L single-use bioreactor in CA
According to AGC Biologics CEO Gustavo Mahler, the additional unit at the facility in Berkeley, California is just the latest expansion by the biologics-focused contract development and manufacturing organization (CDMO).
“Strategically, AGC Biologics plans to sustain our future growth by continuing to invest in our facilities across the globe,” he told Biopharma-Reporter. “The Berkeley, California 2000L SUB expansion is part of our ongoing investment to provide greater capabilities and higher flexibility for our current and future clients.”
He added the capacity was added to meet industry demand for the use of SUBs, “specifically for early-phase projects,” and would complement the 100L and 500L SUBs, and 750L and 3,000L stainless steel tanks housed at the site.
The news is the latest expansion by the biomanufacturing business of Japanese glass solution provider AGC Asahi Glass.
Over the past two years, the firm has become a major biologics CDMO through the acquisitions of Biomeva GmbH and CMC Biologics, and recently consolidated the businesses under the single brand AGC Biologics.
In total the firm now offers 46,000L of microbial and mammalian biomanufacturing capacity through these acquisitions from six facilities in the US, Denmark, Germany and Japan.
